Precision BioSciences Inc (DTIL)vsRegeneron Pharmaceuticals Inc (REGN)
DTIL
Precision BioSciences Inc
$7.28
-3.77%
HEALTHCARE · Cap: $288.76M
REGN
Regeneron Pharmaceuticals Inc
$952.40
-0.32%
HEALTHCARE · Cap: $98.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 37412% more annual revenue ($16.90B vs $45.04M). REGN leads profitability with a 28.5% profit margin vs -85.6%. REGN trades at a lower P/E of 21.0x. REGN earns a higher WallStSmart Score of 80/100 (B+).
DTIL
Avoid26
out of 100
Grade: F
REGN
Strong Buy80
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.6%
Fair Value
$9.38
Current Price
$7.28
$2.10 discount
Margin of Safety
+36.3%
Fair Value
$1500.88
Current Price
$952.40
$548.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Strong operational efficiency at 30.4%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : DTIL
The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.35 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
REGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
REGN scores higher overall (80/100 vs 26/100), backed by strong 28.5% margins and 36.3% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?